The Limits of Genome-wide Methods for Pharmacogenomic Testing
作者： Eric R. Gamazon , Andrew D. Skol , Minoli A. Perera
DOI: 10.1097/FPC.0B013E328350CA5F
关键词:
摘要: Objective The goal of pharmacogenomics is the translation genomic discoveries to individualized patient care. Recent advances in means survey human genetic variation are fundamentally transforming our understanding basis interindividual therapeutic response. The this study was systematically evaluate high-throughput genotyping technologies for their ability assay pharmacogenetically important genes (pharmacogenes). These platforms either being proposed or already widely used clinical implementation; therefore, knowledge coverage pharmacogenes on these would serve better current pharmacogenetic association studies.
researchgate.net 
sci-hub.se 参考文章(40)
TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329
SLCO1B1 variants and statin-induced myopathy--a genomewide study The New England Journal of Medicine. ,vol. 359, pp. 789- 799 ,(2008) , 10.1056/NEJMOA0801936
Jason Lazarou, Bruce H. Pomeranz, Paul N. Corey, Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies JAMA. ,vol. 279, pp. 1200- 1205 ,(1998) , 10.1001/JAMA.279.15.1200
Sharon Marsh, Pui Kwok, Howard L McLeod, None, SNP databases and pharmacogenetics: great start, but a long way to go Human Mutation. ,vol. 20, pp. 174- 179 ,(2002) , 10.1002/HUMU.10115
Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y. Langaee, Charles Eby, Cristi R. King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto J. Vidaillet, Steven H. Yale, Kai Qi Zhang, Richard L. Berg, James K. Burmester, CYP4F2 genetic variant alters required warfarin dose. Blood. ,vol. 111, pp. 4106- 4112 ,(2008) , 10.1182/BLOOD-2007-11-122010
D. Rokitta, U. Fuhr, Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Current Drug Metabolism. ,vol. 11, pp. 153- 161 ,(2010) , 10.2174/138920010791110872
William Y. S. Wang, Bryan J. Barratt, David G. Clayton, John A. Todd, Genome-wide association studies: theoretical and practical concerns Nature Reviews Genetics. ,vol. 6, pp. 109- 118 ,(2005) , 10.1038/NRG1522
Jonathan K. Pritchard, Molly Przeworski, Linkage Disequilibrium in Humans: Models and Data American Journal of Human Genetics. ,vol. 69, pp. 1- 14 ,(2001) , 10.1086/321275
Si Quang Le, Richard Durbin, SNP detection and genotyping from low-coverage sequencing data on multiple diploid samples Genome Research. ,vol. 21, pp. 952- 960 ,(2011) , 10.1101/GR.113084.110
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren, Lennart Holm, Jonatan Lindh, Anders Rane, Mia Wadelius, Panos Deloukas, A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLOS Genetics. ,vol. 5, pp. 1000433- ,(2009) , 10.1371/JOURNAL.PGEN.1000433